Who is sponsoring NCT07304453?

NCT07304453 is sponsored by Karbala University.

What condition does NCT07304453 study?

NCT07304453 studies Trigeminal Neuralgia, Neuropathic Pain.

What drugs are being tested in NCT07304453?

Interventions: Conventional Carbamazepine Therapy, Nucleo CMP and Neurorubine Combination.

What is the status of NCT07304453?

NCT07304453 is currently COMPLETED.

Last reviewed 2025-12-26 · How we verify

Nucleo CMP and Neurorubine Versus Carbamazepine for Classical Trigeminal Neuralgia

NCT07304453 PHASE2 COMPLETED

Trigeminal neuralgia is a severe facial pain condition that significantly impacts quality of life. While the standard medication, carbamazepine, provides relief, it is often associated with side effects and rapid pain recurrence upon discontinuation. This randomized clinical trial compares the efficacy and safety of conventional carbamazepine therapy against a novel combination therapy consisting of Nucleo CMP (cytidine monophosphate) and Neurorubine (Vitamin B complex). The study aims to evaluate pain reduction during active treatment and the sustainability of pain control after treatment cessation.

Details

Lead sponsor	Karbala University
Phase	PHASE2
Status	COMPLETED
Enrolment	38
Start date	Sun Jan 07 2024 00:00:00 GMT+0000 (Coordinated Universal Time)
Completion	Mon Sep 30 2024 00:00:00 GMT+0000 (Coordinated Universal Time)

Conditions

Trigeminal Neuralgia
Neuropathic Pain

Interventions

Conventional Carbamazepine Therapy
Nucleo CMP and Neurorubine Combination

Countries

Iraq